Chen Wei talked about why she was the first to get vaccinated, and what did she say?

On February 29 last year, Chen Wei was the first to receive the new crown vaccine, and it was only put into clinical vaccination 16 days later. Chen Wei is a recognition of his own technology, and he is a doctor who is vaccinated, and if there is an adverse reaction, he can be checked at any time to avoid many adverse reactions to the vaccination of later generations.

She thinks that getting vaccinated is a very good thing and hopes that everyone will have the opportunity to get vaccinated.

She said: "I think that the people who led our team to receive this shot at that time not only accumulated the safety data in the early stage, but also gave courage to the volunteers who carried out the world's first clinical trial of the new crown vaccine.

She said that this would show that our technology is very good, and then she is very confident in the vaccine, and it can also play a particularly good maintenance role.

Chen Wei was the first to be vaccinatedAdenovirus vector vaccineOn February 29 last year, Chen Wei was the first to receive the adenovirus vector vaccine in Wuhan, and the first phase of clinical vaccination was only started 16 days later. She recalls: "One is that we are very confident in our technologyAt the same time, there are risks, but if you don't dare to use it yourself, how can you recruit volunteers to do clinical research?

After vaccination, we took intensive blood samples from ourselves to see when an immune response occurred, with the aim of getting volunteers to draw less blood."

It is worth noting that the day of the interview was not only the day after the vaccine developed by Chen Wei's team was approved for marketing, but also the 55th birthday of Academician Chen Wei.

In this regard, Academician Chen Wei said: "After more than 400 days of hard work, from the very beginning of the project, with the joint efforts of all collaborators and the full support of various departments, the vaccine has been conditionally marketed. It was a very big birthday present for me, and I felt very happy on the one hand, but still very calm on the other.

She also made a birthday wish on the spot - Guotai Min'an!

On the evening of February 26, the second episode of Bai Yansong's new live broadcast program "Bai Q" had a conversation with Chen Wei, an academician of the Chinese Academy of Engineering, to analyze and answer questions about the process of developing vaccines.

On February 29 last year, Chen Wei was the first to receive the adenovirus vector vaccine in Wuhan, and the first phase of the clinical trial was not started until 16 days after vaccination. In the show,Chen Wei recalledOne is that we are very confident in our technology;At the same time, there are risks, but if you don't dare to use it yourself, how can you recruit volunteers to do clinical research?After vaccination, we took intensive blood samples from ourselves to see when an immune response occurred, with the aim of getting volunteers to draw less blood."

Such is the duty and dedication of a military man.

Try the medicine by yourself, and make people admire.

Not slowly, Academician Chen Wei's vaccine was the first to enter clinical trials in China; The two-shot vaccination immunization cycle is a little longer, which may ensure that the two-shot vaccination rate will be reduced, but the strength of the immune response it induces can be its future durability, so it has its own advantages and disadvantages.

Vaccine IntroductionAfter the new crown epidemic hit, not only in our country, but also in the world, vaccines are advancing at a super fast speed. So the so-called "slow", the main reason is that the domestic epidemic is too well controlled, and we can only conduct phase I and phase II clinical trials in people without risk and without virus attack in China. But by the third stage, there must be a high rate of new infections, and there must be a large number of cases to test the protective effect of the vaccine against the disease.

We no longer have this condition in China, so we can only go abroad to carry out phase III clinical trials. It depends on the countries we cooperate with, as well as the institutions we cooperate with, the efficiency between them and the conditions between them, so some countries may not have the highest incidence rate, such as Europe and the United States, where the incidence rate is particularly high, and the progress can be fast. So in this case we are limited by people.

Not only the national decision-making department, but also the public participation in the vaccination is a key issue. Although there are 5 technical routes in China, each vaccine is different in terms of effectiveness, safety and accessibility. In terms of protective effect, the latest mRNA vaccine has a protective effect of more than 90%, and inactivated vaccines and viral vector vaccines are in the range of 70% to 80%.

In terms of safety, medicine is a test science, only through the test, then its safety and certainty depend on how many people have been tested and how long the test has been conducted. The inactivated vaccine has been used by humans for hundreds of years, and the entire earth has used it, so its safety and certainty are the highest.

In terms of the accessibility of vaccines in China, the storage and transportation environment are all 2-8 degrees, and many of our companies have done accelerated trials, even if they are stored at 37 degrees for a few weeks, there is no problem, so when transporting, even if the transportation conditions are worse, our vaccines can ensure quality and efficacy.

In this sense, those temperature conditions that require minus 70 degrees Celsius or minus 20 degrees to 30 degrees Celsius are not suitable for use in developing countries, and even in some economically backward areas of developed countries, it is difficult to vaccinate the population on a large scale. In addition, the reason why China's vaccine accessibility has received so much attention from so many developing countries in the international community is not only the resilience of the vaccine itself, but also related to the construction of a community with a shared future for mankind in China and the concept that China's vaccine is a public good.

In non-epidemic times, the speed of vaccine development can be called superb. Double-shot vaccination reduces the number of vaccinations and facilitates a wide range of vaccinations.

Progress is not slow, and double vaccination has advantages. After all, the virus we are facing is very tenacious, and it will take some time to get a targeted vaccine. Double-shot vaccination is more secure and safer.